Search
# Popular search #
中文站
# Popular search #
山東
甘李藥業股份有限公司的全資子公司，于2019年9月在山東臨沂成立。
主營業務：主要負責藥品及醫療器械的生產等工作。
上海
甘李藥業股份有限公司的全資子公司，于2020年在上海成立。
主營業務：國際商業合作（BD）
香港
甘李藥業股份有限公司的全資子公司，于2020年在中國香港成立。
主營業務：國際商業合作（BD）
美國
甘李藥業股份有限公司的全資子公司，于2014年在美國新澤西州成立。
主營業務：主要負責海外臨床、注冊及業務拓展等工作。
美國
甘李藥業股份有限公司的全資子公司，于2020年在美國新澤西州成立。
主營業務：歐美業務、生產及銷售。
美國
甘李藥業股份有限公司的全資子公司，于2020年在美國新澤西州成立。
主營業務：歐美業務、生產及銷售。
北京
1998年成立，位于北京通州經濟開發區，擁有約20萬平方米的產業園。
北京
甘李藥業股份有限公司的全資子公司，于2007年在北京成立。
主營業務：糖尿病治療配套醫療器械的產品研發設計、新技術開發。
江蘇
甘李藥業股份有限公司的全資子公司，于2015年在江蘇泰州成立。 主營業務：化學藥品生產基地。建設有多肽合成原料藥車間、固體口服制劑車間（片劑）和化學原料藥合成車間以及與之配套的辦公、質檢、倉儲、環保等輔助設施。
江蘇
北京甘甘科技有限公司的全資子公司，于2017年在江蘇泰州成立。 主營業務：著重于將相關研發成果轉換為合規的生產經營活動。主要產品有筆式胰島素注射器（秀霖筆?）、血糖儀、血糖試紙、筆式注射器（預裝式）、一次性胰島素筆用針頭（秀霖針?）等。
德國
甘李藥業股份有限公司的全資子公司，于2021年在德國成立。
主營業務：歐洲業務、臨床及銷售等。
Founded in 1998, the company is located in Beijing, with an industrial base of approximately about 200,000 square meters.
A wholly-owned subsidiary of the Company, established in Linyi, Shandong Province in China, 2019.
Main Business: the production of medicinal products and medical devices.
A wholly-owned subsidiary of the Company, which was established in Beijing, 2007.
Main Business: R&D of medical devices for diabetes treatment
A wholly-owned subsidiary of Gangan Technology, established in Taizhou, Jiangsu Province in China, 2017.
Main Business: Converting relevant R&D results into compliant production and operation activities. The main products include pen-type insulin syringes (GanleePen), blood glucose meters, blood glucose test strips, pre-filled pens, disposable insulin pen needles (GanleeFine?), etc.
A wholly-owned subsidiary of the Company, established in Taizhou, Jiangsu Province in China, 2015
Main Business: Chemical production base, which has a polypeptide synthesis raw material medicine production line, a solid oral preparation production line (tablet) and a chemical raw material medicine synthesis production line, as well as supporting facilities such as office, quality inspection, storage, and environmental protection.
A wholly-owned subsidiary of the Company, established in Hong Kong in China, 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2014.
Main Business: overseas clinical, registration, business development.
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: US & European business, production, and sales.
A wholly-owned subsidiary established by the Company established in Germany in 2021.
Main Business: European business, clinical affairs, and sales.
Founded in 1998, the company is located in Beijing, with an industrial base of approximately about 200,000 square meters.
A wholly-owned subsidiary of the Company, established in Linyi, Shandong Province in China, 2019.
Main Business: the production of medicinal products and medical devices.
A wholly-owned subsidiary of the Company, which was established in Beijing, 2007.
Main Business: R&D of medical devices for diabetes treatment
A wholly-owned subsidiary of Gangan Technology, established in Taizhou, Jiangsu Province in China, 2017.
Main Business: Converting relevant R&D results into compliant production and operation activities. The main products include pen-type insulin syringes (GanleePen), blood glucose meters, blood glucose test strips, pre-filled pens, disposable insulin pen needles (GanleeFine?), etc.
A wholly-owned subsidiary of the Company, established in Taizhou, Jiangsu Province in China, 2015
Main Business: Chemical production base, which has a polypeptide synthesis raw material medicine production line, a solid oral preparation production line (tablet) and a chemical raw material medicine synthesis production line, as well as supporting facilities such as office, quality inspection, storage, and environmental protection.
A wholly-owned subsidiary of the Company, established in Hong Kong in China, 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2014.
Main Business: overseas clinical, registration, business development.
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: International Business Development
A wholly-owned subsidiary established by the Company, established in New Jersey, United States in 2020.
Main Business: US & European business, production, and sales.
A wholly-owned subsidiary established by the Company established in Germany in 2021.
Main Business: European business, clinical affairs, and sales.
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.